 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
0 News |  |
- | prizloncabtagene autoleucel (JNJ-4496) / J&J
Trial completion, Trial completion date: A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma (clinicaltrials.gov) - May 23, 2025
P1, N=10, Completed, Sponsor: Peking Union Medical College Hospital
Trial completion date: Oct 2022 --> Jun 2024 | Recruiting --> Completed
- | prizloncabtagene autoleucel (JNJ-4496) / J&J
Trial completion: A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects (clinicaltrials.gov) - May 23, 2025
P1, N=25, Completed, Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine
Trial completion date: Oct 2022 --> Jun 2024 | Recruiting --> Completed Active, not recruiting --> Completed
- prizloncabtagene autoleucel (JNJ-4496) / J&J
LONG-TERM CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA TREATED WITH PRIZLONCABTAGENE AUTOLEUCEL (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_2918;
Prizlon-cel demonstrated a favorable safety profile, along with deep and durable responses in patients with r/r B-NHL, particularly in those with LBCL. The long-term follow-up results suggested the curative potential of prizlon-cel in this patient population.
- prizloncabtagene autoleucel (JNJ-4496) / J&J
A GLOBAL PHASE 1B STUDY OF JNJ-90014496, A CD19/CD20 BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) (Gold Hall) - May 15, 2025 - Abstract #EHA2025EHA_1040;
A CRR of 80% and no G3/4 ICANS (5% G1) or G3/4 CRS from this first global study are promising confirm previous findings in Chinese pts and compare favorably to historical data with approved anti-CD19 CAR T-cell therapies. Longer follow-up is ongoing to confirm durability and further deepening of responses.
- prizloncabtagene autoleucel (JNJ-4496) / J&J
A GLOBAL PHASE 1B STUDY OF JNJ-90014496, A CD19/CD20 BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) (Room B) - May 4, 2025 - Abstract #ICML2025ICML_961;
- || prizloncabtagene autoleucel (JNJ-4496) / J&J
P1 data, Journal: A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. (Pubmed Central) - Apr 3, 2025
P1
Patients with CD19 and/or CD20-positive R/R B-NHL received a 3-day lymphodepletion (cyclophosphamide: 300 mg/m2 per day; fludarabine: 30 mg/m2 per day) followed by an IV dose of prizlon-cel...Prizlon-cel showed a favorable safety profile and a high and durable response in patients with r/r B-NHL, suggesting a promising treatment option for patients with r/r B-NHL. (ClinicalTrials.gov number: NCT04317885, NCT04655677, NCT04696432, NCT04693676).
- | prizloncabtagene autoleucel (JNJ-4496) / J&J
Journal: Prizloncabtagene autoleucel: a new CAR T cell for B-NHL. (Pubmed Central) - Apr 3, 2025
(ClinicalTrials.gov number: NCT04317885, NCT04655677, NCT04696432, NCT04693676). No abstract available
- || prizloncabtagene autoleucel (JNJ-4496) / J&J
Enrollment change: A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 26, 2024
P1, N=230, Recruiting, Sponsor: Janssen Research & Development, LLC
No abstract available N=104 --> 230
- | prizloncabtagene autoleucel (JNJ-4496) / J&J
Phase classification, Enrollment change, Trial completion date, Trial primary completion date: ELEVATION: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (clinicaltrials.gov) - Nov 6, 2024
P1/2, N=112, Recruiting, Sponsor: Shanghai AbelZeta Ltd.
N=104 --> 230 Phase classification: P1b/2 --> P1/2 | N=72 --> 112 | Trial completion date: Mar 2027 --> Dec 2027 | Trial primary completion date: Mar 2027 --> Oct 2025
- | prizloncabtagene autoleucel (JNJ-4496) / J&J
Trial completion date: A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 2, 2024
P1, N=104, Recruiting, Sponsor: Janssen Research & Development, LLC
Phase classification: P1b/2 --> P1/2 | N=72 --> 112 | Trial completion date: Mar 2027 --> Dec 2027 | Trial primary completion date: Mar 2027 --> Oct 2025 Trial completion date: Oct 2027 --> Oct 2028
- | prizloncabtagene autoleucel (JNJ-4496) / J&J
Trial completion date: A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 6, 2023
P1, N=104, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Oct 2027 --> Oct 2028 Trial completion date: Apr 2027 --> Oct 2027
- || prizloncabtagene autoleucel (JNJ-4496) / J&J
Enrollment change, Trial completion date: A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 18, 2023
P1, N=92, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Apr 2027 --> Oct 2027 N=52 --> 92 | Trial completion date: Oct 2027 --> Apr 2027
- prizloncabtagene autoleucel (JNJ-90014496) / J&J
C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in ... (SDCC - Room 6A) - Nov 3, 2023 - Abstract #ASH2023ASH_5209;
N=52 --> 92 | Trial completion date: Oct 2027 --> Apr 2027 At a longer median follow-up of 23.9 months, C-CAR039 demonstrated a favorable safety profile with deep and durable response in pts with r/r B-NHL, especially in LBCL pts.
- || prizloncabtagene autoleucel (JNJ-4496) / J&J
Enrollment change, Trial completion date, Trial primary completion date: A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 13, 2023
P1, N=52, Recruiting, Sponsor: Janssen Research & Development, LLC
At a longer median follow-up of 23.9 months, C-CAR039 demonstrated a favorable safety profile with deep and durable response in pts with r/r B-NHL, especially in LBCL pts. N=15 --> 52 | Trial completion date: Jul 2038 --> Oct 2027 | Trial primary completion date: May 2025 --> May 2026
- || prizloncabtagene autoleucel (JNJ-4496) / J&J
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma (clinicaltrials.gov) - May 31, 2023
P1, N=7, Active, not recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
N=15 --> 52 | Trial completion date: Jul 2038 --> Oct 2027 | Trial primary completion date: May 2025 --> May 2026 Recruiting --> Active, not recruiting | N=10 --> 7 | Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Jul 2023
- || prizloncabtagene autoleucel (JNJ-4496) / J&J
Enrollment closed, Trial completion date, Trial primary completion date: A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects (clinicaltrials.gov) - May 26, 2023
P1, N=25, Active, not recruiting, Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine
Recruiting --> Active, not recruiting | N=10 --> 7 | Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Jul 2023 Recruiting --> Active, not recruiting | Trial completion date: Aug 2021 --> Dec 2023 | Trial primary completion date: Aug 2021 --> Jun 2023
- || prizloncabtagene autoleucel (JNJ-4496) / J&J
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma (clinicaltrials.gov) - May 25, 2023
P1, N=17, Active, not recruiting, Sponsor: First Affiliated Hospital of Zhejiang University
Recruiting --> Active, not recruiting | Trial completion date: Aug 2021 --> Dec 2023 | Trial primary completion date: Aug 2021 --> Jun 2023 Recruiting --> Active, not recruiting | N=10 --> 17 | Trial completion date: Oct 2022 --> Apr 2024 | Trial primary completion date: Jul 2022 --> Dec 2023
- || prizloncabtagene autoleucel (JNJ-4496) / J&J
Enrollment open: A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Aug 11, 2022
P1, N=15, Recruiting, Sponsor: Cellular Biomedicine Group Ltd.
Recruiting --> Active, not recruiting | N=10 --> 17 | Trial completion date: Oct 2022 --> Apr 2024 | Trial primary completion date: Jul 2022 --> Dec 2023 Not yet recruiting --> Recruiting
- || prizloncabtagene autoleucel (JNJ-4496) / J&J
New P1 trial: A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 15, 2022
P1, N=15, Not yet recruiting, Sponsor: Cellular Biomedicine Group Ltd.
- | prizloncabtagene autoleucel (JNJ-4496) / J&J
New P1 trial, CAR T-Cell Therapy: A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 7, 2021
P1, N=18, Recruiting, Sponsor: Peking University
- C-CAR039 / Cellular Biomedicine, Tongji University
[VIRTUAL] Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2559;
P1
The early clinical efficacy signal is encouraging and compares favorably to anti-CD19 CAR-T and peer therapies . These findings will be evaluated in more patients with longer follow-up to confirm safety, efficacy and duration of response.
- | prizloncabtagene autoleucel (JNJ-4496) / J&J
New P1 trial: A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 5, 2021
P1, N=10, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | prizloncabtagene autoleucel (JNJ-4496) / J&J
New P1 trial: A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 4, 2021
P1, N=10, Recruiting, Sponsor: First Affiliated Hospital of Zhejiang University
- | prizloncabtagene autoleucel (JNJ-4496) / J&J
New P1 trial: A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 7, 2020
P1, N=10, Recruiting, Sponsor: Peking Union Medical College Hospital
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHL () - Nov 5, 2020 - Abstract #ASH2020ASH_5147;
P1
The early clinical efficacy signal is encouraging and compares favorably to anti-CD19 CAR-T therapies. These findings need to be evaluated in more patients with longer follow-up to confirm safety, efficacy and duration of response.
- | prizloncabtagene autoleucel (JNJ-4496) / J&J
Enrollment change: A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects (clinicaltrials.gov) - Sep 24, 2020
P1, N=25, Recruiting, Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine
These findings need to be evaluated in more patients with longer follow-up to confirm safety, efficacy and duration of response. N=10 --> 25
- | prizloncabtagene autoleucel (JNJ-4496) / J&J
New P1 trial: A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects (clinicaltrials.gov) - Mar 23, 2020
P1, N=10, Recruiting, Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine